Programa de educación emocional PISOTÓN para la promoción de la salud mental de niños y niñas en territorios afectados por el conflicto armado colombiano: Un estudio comparativo

Estudio comparativo con medición inicial y medición posterior a la implementación del Programa de Educación Emocional Pisotón. Muestra de 6.808 niños y niñas entre 3 y 7 años en 18 departamentos afectados por el conflicto armado colombiano. El instrumento fue Fábulas de Düss, analizándose las respuestas a partir de la clasificación de Bell (1992). Se realizaron pruebas de comparación de proporciones mediante Chi cuadrado y prueba Z, estudiando diferencias significativas entre grupos. En las fábulas 1 a 7 y 9 siempre se cumple que la proporción en el grupo “significativo" y “resistencia” es menor que la proporción en el grupo “normal” después de la implementación del Programa, lo cual indica un aumento estadísticamente significativo en el número de participantes ubicados en la categoría Normal

Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

Funder: European Society of Intensive Care Medicine; doi: http://dx.doi.org/10.13039/501100013347Funder: Flemish Society for Critical Care NursesAbstract: Purpose: Intensive care unit (ICU) patients are particularly susceptible to developing pressure injuries. Epidemiologic data is however unavailable. We aimed to provide an international picture of the extent of pressure injuries and factors associated with ICU-acquired pressure injuries in adult ICU patients. Methods: International 1-day point-prevalence study; follow-up for outcome assessment until hospital discharge (maximum 12 weeks). Factors associated with ICU-acquired pressure injury and hospital mortality were assessed by generalised linear mixed-effects regression analysis. Results: Data from 13,254 patients in 1117 ICUs (90 countries) revealed 6747 pressure injuries; 3997 (59.2%) were ICU-acquired. Overall prevalence was 26.6% (95% confidence interval [CI] 25.9–27.3). ICU-acquired prevalence was 16.2% (95% CI 15.6–16.8). Sacrum (37%) and heels (19.5%) were most affected. Factors independently associated with ICU-acquired pressure injuries were older age, male sex, being underweight, emergency surgery, higher Simplified Acute Physiology Score II, Braden score 3 days, comorbidities (chronic obstructive pulmonary disease, immunodeficiency), organ support (renal replacement, mechanical ventilation on ICU admission), and being in a low or lower-middle income-economy. Gradually increasing associations with mortality were identified for increasing severity of pressure injury: stage I (odds ratio [OR] 1.5; 95% CI 1.2–1.8), stage II (OR 1.6; 95% CI 1.4–1.9), and stage III or worse (OR 2.8; 95% CI 2.3–3.3). Conclusion: Pressure injuries are common in adult ICU patients. ICU-acquired pressure injuries are associated with mainly intrinsic factors and mortality. Optimal care standards, increased awareness, appropriate resource allocation, and further research into optimal prevention are pivotal to tackle this important patient safety threat

Correction to: Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

The original version of this article unfortunately contained a mistake

Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

Funder: European Society of Intensive Care Medicine; doi: http://dx.doi.org/10.13039/501100013347Funder: Flemish Society for Critical Care NursesAbstract: Purpose: Intensive care unit (ICU) patients are particularly susceptible to developing pressure injuries. Epidemiologic data is however unavailable. We aimed to provide an international picture of the extent of pressure injuries and factors associated with ICU-acquired pressure injuries in adult ICU patients. Methods: International 1-day point-prevalence study; follow-up for outcome assessment until hospital discharge (maximum 12 weeks). Factors associated with ICU-acquired pressure injury and hospital mortality were assessed by generalised linear mixed-effects regression analysis. Results: Data from 13,254 patients in 1117 ICUs (90 countries) revealed 6747 pressure injuries; 3997 (59.2%) were ICU-acquired. Overall prevalence was 26.6% (95% confidence interval [CI] 25.9–27.3). ICU-acquired prevalence was 16.2% (95% CI 15.6–16.8). Sacrum (37%) and heels (19.5%) were most affected. Factors independently associated with ICU-acquired pressure injuries were older age, male sex, being underweight, emergency surgery, higher Simplified Acute Physiology Score II, Braden score 3 days, comorbidities (chronic obstructive pulmonary disease, immunodeficiency), organ support (renal replacement, mechanical ventilation on ICU admission), and being in a low or lower-middle income-economy. Gradually increasing associations with mortality were identified for increasing severity of pressure injury: stage I (odds ratio [OR] 1.5; 95% CI 1.2–1.8), stage II (OR 1.6; 95% CI 1.4–1.9), and stage III or worse (OR 2.8; 95% CI 2.3–3.3). Conclusion: Pressure injuries are common in adult ICU patients. ICU-acquired pressure injuries are associated with mainly intrinsic factors and mortality. Optimal care standards, increased awareness, appropriate resource allocation, and further research into optimal prevention are pivotal to tackle this important patient safety threat

Études cristallographiques du récepteur de l'activateur du plasminogène de type urokinase en complexe avec un peptide antagoniste

L'interaction entre le récepteur de l'activateur du plasminogène de type urokinase (uPAR) et l'activateur du plasminogène de type urokinase (uPA) joue un rôle important dans de nombreuses conditions physiologiques aussi bien que pathologiques liées à la dégradation de la matrice extracellulaire : réparation du tissu, recrutement des neutrophiles pendant une inflammation, invasion tumorale et prolifération métastatique. Le couple formé par uPAR et uPA est capable d'interagir avec différents protéines pour participer à des processus d'adhésion et de migration cellulaire, de signalisation et de chimiotactisme. De nombreuses évidences démontrent la participation du couple uPAR/uPA dans les processus de prolifération cancéreuse et de prolifération des métastases via l'activation péricellulaire du plasminogène, mais aussi par les différentes interactions qu'il peut établir avec d'autres protéines. De ce fait, l'inhibition de l'interaction entre uPAR et uPA a un potentiel thérapeutique très intéressante. La structure tridimensionnelle d'un complexe entre uPAR et un peptide antagoniste de son interaction avec uPA a été résolue à 2.7 Å de résolution. Cette structure révèle le mécanisme par lequel le peptide inhibe l'interaction uPAR:uPA, établissant les bases pour l'optimisation des peptides antagonistes ainsi que le développement de nouvelles molécules dans un but thérapeutique. Ces résultats nous ont permit de proposer un modèle du complexe uPAR:uPA et comprendre comment ce couple pourrait interagir avec ses différents partenaires.The interaction between the urokinase type plasminogen activator receptor (uPAR) and the urokinase type plasminogen activator (uPA) plays an important role in several physiological or pathological conditions in which the extracellular matrix degradation takes place: tissue remodeling, neutrophile recruitment during inflammation, tumoral invasion and metastasis. The couple formed by uPAR and uPA can interact with different proteins participating in cellular adhesion and migration, signal transduction or chemotaxis. The implication of uPAR/uPA couple in cancer proliferation and metastasis through pericellular activation of the plasminogen has been widely demonstrated. Inhibition of the interaction between uPAR and uPA becomes an interesting therapeutic target. The three dimensional structure of a complex between uPAR and an antagonist peptide of uPA's interaction was solved at 2.7 Å. This structure suggests a mechanism for the inhibition of the uPAR/uPA interaction, establishing the bases for the optimization of antagonist peptides as well as new structures with a therapeutic goal. In addition, these results allowed us to propose a model for the uPAR/uPA complex and to understand how this couple may interact with its different partners.PARIS-Museum Hist.Naturelle (751052304) / SudocSudocFranceF

Insights into the activation of Kinesin1 from the molecular characterisation of JIP3/4 binding to Kif5b

International audienceAbstract Whereas our understanding of kinesin auto-inhibition mechanisms is improving faster, important insights into kinesin activation mechanisms such as those controlled by cargo-motor adaptors are still missing. JIP3 and JIP4 are versatile motor-cargo adaptors for kinesin1 and dynein-dynactin motors enabling bi-directional transport on microtubules. JIP3 activates kinesin1 heavy chains, independently of kinesin1 light chains. In this report, we characterize the molecular details of the binding of the kinesin1 heavy chain, Kif5b to the motor-cargo adaptors, JIP3 and JIP4, using biophysical approaches. The definition of the exact binding site of Kif5b, as well as the specificity of interaction between JIP3 and JIP4 provide new insights into kinesin1 activation

How myosin motors power cellular functions - an exciting journey from structure to function

International audienc

Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide

We report the crystal structure of a soluble form of human urokinase-type plasminogen activator receptor (uPAR/CD87), which is expressed at the invasive areas of the tumor-stromal microenvironment in many human cancers. The structure was solved at 2.7 Å in association with a competitive peptide inhibitor of the urokinase-type plasminogen activator (uPA)–uPAR interaction. uPAR is composed of three consecutive three-finger domains organized in an almost circular manner, which generates both a deep internal cavity where the peptide binds in a helical conformation, and a large external surface. This knowledge combined with the discovery of a convergent binding motif shared by the antagonist peptide and uPA allowed us to build a model of the human uPA–uPAR complex. This model reveals that the receptor-binding module of uPA engages the uPAR central cavity, thus leaving the external receptor surface accessible for other protein interactions (vitronectin and integrins). By this unique structural assembly, uPAR can orchestrate the fine interplay with the partners that are required to guide uPA-focalized proteolysis on the cell surface and control cell adhesion and migration